TY - JOUR T1 - 测试支气管扩张响应JF - 欧洲呼吸杂志JO - 欧洲呼吸j执行 - 10.1183 / 13993003.02104-2019 VL - 54 - 6 SP - 1902104 AU - 詹森，和Christer AU - Malinovschi，安德烈AU - 阿马拉尔，安德烈F.S.AU - Accordini，西蒙娜AU - 布斯凯，让非盟 - 比伊斯特，A.索尼娅AU - 加西亚 - Aymerich，朱迪思AU - Gnatiuc，路易莎AU - 潭，万盟 - 托伦谢尔AU - Zuberbier，托斯滕AU - 伯尼，彼得A2- , Y1 - 2019/12/01 UR - //www.qdcxjkg.com/content/54/6/1902104.abstract N2 - We thank M.R. Miller for his comments on our paper regarding bronchodilator reversibility in asthma and COPD [1]. We agree that it is important to look at different ways of defining bronchodilator reversibility. In our analysis, we investigated both flow-related bronchodilator reversibility, defined by the change in forced expiratory volume in 1 s (FEV1), and volume-related bronchodilator reversibility, defined by the change in forced vital capacity. We also looked at both the change in lung function parameters expressed as percent of the baseline value and the change in FEV1 standardised by the subject's predicted value. The latter was evaluated to control for the sex, age and height dependency of lung function. The results when reversibility was expressed as percent of the predicted value (in supplementary tables E3 and E4) [1] were the same as when reversibility was expressed as percent of the baseline value. Our interpretation was therefore that, in the present study, neither flow-related nor volume-related bronchodilator reversibility were independently associated with the symptom burden, health status or dyspnoea in the COPD population.Neither flow-related nor volume-related bronchodilator reversibility were independently associated with the symptom burden, health status or dyspnoea in the COPD population http://bit.ly/2rigD1r ER -